Skip to main content

Table 1 Genotype frequencies of polymorphisms in NOD1, NOD2, TLR2, TLR4 and TLR9 and endometrial cancer risk

From: Toll-Like Receptor (TLR) and Nucleosome-binding Oligomerization Domain (NOD) gene polymorphisms and endometrial cancer risk

Polymorphism

Genotypes

Cases n (%)

Controls n (%)

χ2

OR (95% CI) and p value

 

TT

119 (62.3)

176 (60.5)

  

NOD1 (rs2075822)

TC

62 (32.5)

105 (36.1)

 

1.188

 

CC

10 (5.2)

10 (3.4)

p = 0.497

(0.774-1.823) p = 0.432

 

TC+CC

72 (37.7)

115 (39.5)

  
 

AA

104 (54.5)

152 (52.2)

  

NOD1 (rs2907749)

AG

68 (35.6)

118 (40.6)

 

1.156

 

GG

19 (9.9)

21 (7.2)

p = 0.392

(0.759-1.761) p = 0.499

 

AG+GG

87 (45.5)

139 (47.8)

  
 

CC

114 (59.7)

168 (57.7)

  

NOD1 (rs2907748)

CT

64 (33.5)

110 (37.8)

 

1.156

 

TT

13 (6.8)

13 (4.5)

p = 0.400

(0.755-1.769) p = 0.505

 

CT+TT

77 (40.3)

123 (42.3)

  
 

CC

182 (95.3)

282 (96.9)

 

1.549

NOD2 (rs5743260)

CT

9 (4.7)

9 (3.1)

p = 0.359

(0.604-3.977) p = 0.363

 

TT

0 (0.0)

0 (0.0)

  
 

CC

178 (93.2)

263 (90.4)

 

0.928

NOD2 (rs2066844)

CT

13 (6.8)

28 (9.6)

p = 0.278

(0.407-2.116) p = 0.859

 

TT

0 (0.0)

0 (0.0)

  
 

GG

187 (97.9)

282 (96.9)

 

0.636

NOD2 (rs2066845)

GC

4 (2.1)

9 (3.1)

p = 0.508

(0.143-2.835) p = 0.553

 

CC

0 (0.0)

0 (0.0)

  
 

GG

177 (92.7)

275 (94.5)

 

1.190

TLR2 (rs5743708)

GA

14 (7.3)

16 (5.5)

p = 0.416

(0.501-2.826) p = 0.694

 

AA

0 (0.0)

0 (0.0)

  
 

AA

163 (85.3)

258 (88.7)

  

TLR4 (rs4986790)

AG

25 (13.1)

31 (10.6)

 

1.098

 

GG

3 (1.6)

2 (0.7)

p = 0.449

(0.573-2.101) p = 0.778

 

AG+GG

28 (14.7)

33 (11.3)

  
 

TT

85 (44.5)

116 (39.9)

  

TLR9 (rs5743836)

TC

79 (41.4)

128 (44.0)

 

0.781

 

CC

27 (14.1)

47 (16.1)

p = 0.581

(0.511-1.195) p = 0.255

 

TC+CC

106 (55.5)

175 (60.1)

  
 

TT

138 (72.25)

187 (64.3)

  

TLR9 (rs187084)

TC

49 (25.65)

88 (30.2)

 

0.675

 

CC

4 (2.1)

16 (5.5)

p = 0.076

(0.428-1.064) p = 0.091

 

TC+CC

53 (27.75)

104 (35.7)

  
  1. NB: Χ2 - Wild-type genotype versus heterozygous genotype versus homozygous variant genotype. Odds ratios for polymorphisms in NOD1, TLR4 and TLR9 were calculated as follows: Wild Type genotype compared to combination of heterozygous and homozygous variant genotypes. Odds ratios for polymorphisms in NOD2 and TLR2 were calculated as follows: Wild Type genotype compared to heterozygous genotype. All Odds Ratios were adjusted for age, BMI, diabetes, HBP, history of cancer, HT, smoking and alcohol use.